Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Wilson

Showing results (131-140 of 175) with videos related to

Pageof 18
Sort By:
British Journal of Haematology|November 22, 2020
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trialMarquita Camilleri, Jonathan Sive, William Wilson, et al.
Frontiers in Oncology|August 9, 2021
Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple MyelomaCatherine S Y Lecat, Jessica B Taube, William Wilson, et al.
American Journal of Medical Genetics. Part A|June 7, 2007
Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndromeKaren W Gripp, Angela E Lin, Linda Nicholson, et al.
Frontiers in Immunology|March 15, 2021
Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple MyelomaLydia Lee, Nouf Alrasheed, Garima Khandelwal, et al.
British Journal of Haematology|March 26, 2026
Results from the prospective phase 2 multicentre UK PBSC haplo trial using PTCy pre- or post-stem cellsHugues deLavallade, William Wilson, Rachel Protheroe, et al.
British Journal of Haematology|August 20, 2024
PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's MacroglobulinaemiaJaimal Kothari, Toby Eyre, Ali Rismani, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL StudySamantha C Burnham, Nandini Raghavan, William Wilson, et al.
Therapeutic Advances in Medical Oncology|November 12, 2020
COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort studyValerie E Crolley, Daire Hanna, Nalinie Joharatnam-Hogan, et al.
American Journal of Industrial Medicine|January 31, 2019
Occupational medicine clinical practice data reveal increased injury rates among Hispanic workersScott M Riester, Karyn L Leniek, Ashley D Niece, et al.
Cancer Medicine|February 4, 2026
A Digital Health Approach to Improve Compliance With Surveillance Colonoscopy Guidelines: The SCOPES Program: Study protocol for a stepped-wedge cluster trialErin L Symonds, Geraldine Laven-Law, Isabelle Keel, et al.
Pageof 18

Showing results (131-140 of 175) with videos related to

Sort By:
Pageof 18
British Journal of Haematology|November 22, 2020
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trialMarquita Camilleri, Jonathan Sive, William Wilson, et al.
Frontiers in Oncology|August 9, 2021
Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple MyelomaCatherine S Y Lecat, Jessica B Taube, William Wilson, et al.
American Journal of Medical Genetics. Part A|June 7, 2007
Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndromeKaren W Gripp, Angela E Lin, Linda Nicholson, et al.
Frontiers in Immunology|March 15, 2021
Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple MyelomaLydia Lee, Nouf Alrasheed, Garima Khandelwal, et al.
British Journal of Haematology|March 26, 2026
Results from the prospective phase 2 multicentre UK PBSC haplo trial using PTCy pre- or post-stem cellsHugues deLavallade, William Wilson, Rachel Protheroe, et al.
British Journal of Haematology|August 20, 2024
PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's MacroglobulinaemiaJaimal Kothari, Toby Eyre, Ali Rismani, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL StudySamantha C Burnham, Nandini Raghavan, William Wilson, et al.
Therapeutic Advances in Medical Oncology|November 12, 2020
COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort studyValerie E Crolley, Daire Hanna, Nalinie Joharatnam-Hogan, et al.
American Journal of Industrial Medicine|January 31, 2019
Occupational medicine clinical practice data reveal increased injury rates among Hispanic workersScott M Riester, Karyn L Leniek, Ashley D Niece, et al.
Cancer Medicine|February 4, 2026
A Digital Health Approach to Improve Compliance With Surveillance Colonoscopy Guidelines: The SCOPES Program: Study protocol for a stepped-wedge cluster trialErin L Symonds, Geraldine Laven-Law, Isabelle Keel, et al.
Pageof 18